论文部分内容阅读
目的观察红花黄色素对老年非ST段抬高型心肌梗死(NSTEMI)者血hs-CRP、HCY、UA及LVEDD、LVEF影响，探讨红花黄色素心肌保护的可能机制。方法选择2013年10月~2014年12月住院NSTEMI患者60例，平均年龄(80.57±8.13)岁，随机分为对照组(n=30)：常规治疗(硝酸酯、β-阻滞剂、调脂、抗血小板、抗凝等)，药物组(n=30)：常规治疗+红花黄色素注射液(100mg，1次/d，静滴)。两组患者于治疗前、2w时检测血hs-CRP、HCY、UA水平，观察LVEDD、LVEF变化。结果①两组患者年龄、性别及伴发糖尿病、高血压方面无差异(>0.05)；②两组患者治疗后血hs-CRP、HCY较治疗前降低，药物组降低较对照组明显(0.05)；③2w时各组患者LVEDD较治疗前降低，药物组降低较对照组明显(<0.05)；LVEF治疗后较治疗前增加，药物组较对照组增加显著(0.05);2 The level of hs-CRP/HCY in two groups after the treatment were lower than before, there was a significantly lower in the treatment group ( 0.05). 3 At the end of 2nd week LVEDD was decreaser than before treatment in two groups and the trend is obvious in the treatment group( <0.05). the same as LVEF is increaser than before treatment in two groups, and more obvious in the treatment group ( <0.05). Conclusion 1 The level of hs-CRP/HCY were reduced by SY in the elderly patients with NSTEMI who received the treatment for two weeks. 2 There was an effect of SY that can decline LVEDD, improve LVEF and make the left ventricular systolic function of heart better.